Top Markets
Coin of the day
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc.

CNSP
株式のランク #33273
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily... CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
株価
$5.47
最終同期: 2026-08-14
時価総額
$7.99M
変化(1日)
6.21%
変化(1年)
7.47%
US
取引 CNS Pharmaceuticals, Inc. (CNSP)

カテゴリー

CNS Pharmaceuticals, Inc.(CNSP)の配当履歴
CNS Pharmaceuticals, Inc.(証券コード:CNSP)は合計で0回の配当を行いました。
すべての配当の合計(株式分割調整済み)は:0.00
配当利回り(TTM):0
2026から2026までのCNS Pharmaceuticals, Inc.(CNSP)の配当履歴
年間配当支払い
配当(株式分割調整済み) 変化
提供された日付のデータは十分ではありません。
すべての配当支払いの一覧
配当 変化
提供された日付のデータは十分ではありません。
同業他社や競合企業の配当履歴